Barclays
MTNB icon

Barclays’s Matinas BioPharma MTNB Stock Holding History

Barclays’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-297
Closed -$16K – 5010
2021
Q1 		$16K Buy
+297
New +$19.9K ﹤0.01% 4401
2020
Q4 		– Sell
-252
Closed -$10K – 5087
2020
Q3 		$10K Buy
+252
New +$10K ﹤0.01% 5012
2019
Q4 		– Hold
0
– – – 6642
2019
Q3 		– Hold
0
– – – 6981
2019
Q2 		– Sell
-1,353
Closed -$65K – 7126
2019
Q1 		$74K Buy
+1,353
New +$72.9K ﹤0.01% 5595
2018
Q3 		– Sell
-20
Closed – – 7289
2018
Q2 		$0 Sell
20
-252
-93% -$7.28K ﹤0.01% 7163
2018
Q1 		$11K Buy
272
+65
+31% +$3.44K ﹤0.01% 6636
2017
Q4 		$12K Buy
207
+183
+763% +$11.8K ﹤0.01% 6472
2017
Q3 		$2K Buy
24
+23
+2,300% +$1.53K ﹤0.01% 6677
2017
Q2 		$0 Buy
+1
New +$134 ﹤0.01% 6822

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Barclays's MTNB Position: Q2 2021 in Review

Barclays sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 297 shares — an estimated $16K sold.

Barclays first reported a position in MTNB in Q2 2017 and held it in 8 quarters. The position peaked at $74K in Q1 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • Barclays reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • Barclays sold 297 Matinas BioPharma shares in Q2 2021, an estimated $16K.
  • Barclays first reported a position in Matinas BioPharma in Q2 2017 and held it in 8 quarters.
  • Barclays's Matinas BioPharma position peaked at $74K in Q1 2019.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.